Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

onferences that

will be webcast. Both conferences will occur later this month and

include:

o Rodman & Renshaw 10th Annual Healthcare Conference

o Lazard Capital Markets 5th Annual Healthcare Conference

"The interim analysis of our Phase 3 IMPACT trial was an important milestone for us. We were encouraged to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a patient population that currently has few appealing treatment options available," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Importantly, the results from this interim analysis are consistent with those from our previous Phase 3 studies at a similar follow-up time, and we are looking forward to the final analysis of the IMPACT trial in the middle of next year."

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of Sangamo,s ZFP Therapeutic(TM) development programs and an ... on Wednesday, June 10, 2009 at the Eighth Annual Needham ... City. , , The presentation will be webcast live ...
... June 3 Carl Icahn announced today that Biogen is acting ... of shareholders in order the prevent the votes that have been ... to attempt to keep two of the Icahn nominees from winning ... Mulligan, a prominent scientist and physician, may be kept from legitimately ...
... SAN MATEO, Calif., June 3 NeurogesX, ... focused on developing and commercializing novel pain management therapies, ... Officer, is scheduled to present at the 8th Annual ... , , Mr. DiTonno and Stephen Ghiglieri, Chief ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 2NeurogesX to Present at Needham Life Sciences Conference 2NeurogesX to Present at Needham Life Sciences Conference 3
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... Wis. No matter how many times it,s ... social, communicating creatures. , But by using ... organisms radically alter their behavior to suit their ... of them are present, and act accordingly. , ... millions, it may change from innocuous to pathogenic, ...
(Date:9/18/2014)... tiny strands of nucleic acid that contain instructions for ... data, our DNA is copied into RNA molecules, which ... in our cells. , Several years ago, scientists ... other known RNAs, this molecule is circular, and was ... has been known about how they are produced. Moreover, ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... International Osteoporosis Foundation (IOF) and the European Society for ... will hold a joint global congress, IOF WCO- ECCEO10, ... Complete programme information, online registration and abstract submission ... IOF WCO-ECCEO10 will be an excellent forum for ...
... no nervous system or brain. So how do individual ... called a biofilm "decide" between different physiological processes (such ... biofilm)? In the prestigious 2009 Fleming lecture, ... Harrogate, (Monday 30 March) Dr Nicola Stanley-Wall from the ...
... a gene that suppresses tumor growth in melanoma, the deadliest ... the journal Nature Genetics as part of a ... skin cancer and many other types of cancer. ... had changes, or mutations, in genes that code for matrix ...
Cached Biology News:Meet-the-expert sessions on 20 key topics to enhance scientific programme of IOFWCO-ECCEO10 2Skin cancer study uncovers new tumor suppressor gene 2Skin cancer study uncovers new tumor suppressor gene 3
Active GST Protein...
... Cyno Serum • Cyno serum is collected off ... and 5-7 years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: Potassium ... Alsevers N-05: ACD N-07: CPD ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
adult...
Biology Products: